<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02798029</url>
  </required_header>
  <id_info>
    <org_study_id>2015-0874</org_study_id>
    <secondary_id>NCI-2016-01180</secondary_id>
    <secondary_id>2015-0874</secondary_id>
    <nct_id>NCT02798029</nct_id>
  </id_info>
  <brief_title>Frameless Fractionated Stereotactic Radiation in Treating Patients With Brain Metastases</brief_title>
  <official_title>A Phase II Study of the Efficacy, Safety, and Cost of Frameless Fractionated Stereotactic Radiation for Parenchymal Brain Metastases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies the safety and efficacy of frameless fractionated stereotactic&#xD;
      radiation therapy for brain metastases. Frameless fractionated stereotactic radiosurgery is a&#xD;
      specialized radiation therapy that delivers 3 to 5, high dose fractions of radiation directly&#xD;
      to the brain lesions while sparing normal tissues.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To assess the efficacy and safety of frameless fractionated stereotactic radiation therapy&#xD;
      (FFSRT) on the treatment of solitary and oligometastatic brain metastases in the MD Anderson&#xD;
      Houston Area Locations, MD Anderson Radiation Treatment Centers in New Mexico, MD Anderson&#xD;
      affiliates and the main campus of MD Anderson, for patients unable or unwilling to undergo&#xD;
      frame-based stereotactic radiosurgery (SRS).&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To assess 6-month local control, intracranial progression-free survival and overall&#xD;
      survival.&#xD;
&#xD;
      II. To collect data on charges and reimbursements of patients treated with FFSRT to compare&#xD;
      those charges and reimbursements if the same patients had been treated with single-fraction,&#xD;
      frame-based gamma knife SRS.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Patients undergo FFSRT daily over 30 minutes for 3-5 days.&#xD;
&#xD;
      After completion of study treatment, patients are followed up every 3 months for up to 1&#xD;
      year.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 8, 2016</start_date>
  <completion_date type="Anticipated">August 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of lesion failure based on imagining assessments for each lesion</measure>
    <time_frame>Up to 1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Rates of local control</measure>
    <time_frame>Up to 1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Intracranial progression free survival (PFS)</measure>
    <time_frame>From enrollment to either the first observation of progression disease in the brain or death due to any cause, assessed up to 1 year</time_frame>
    <description>Will be summarized using the Kaplan-Meier method and the 50th percentile of the Kaplan-Meier distribution will determine the median intracranial PFS.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Will be summarized using the Kaplan-Meier method and the 50th percentile of the Kaplan-Meier distribution will determine the median intracranial OS.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cost data</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Will be summarized using descriptive statistics such as mean, median, standard deviation, and range. Comparisons in cost between treatment modalities will be evaluated using a paired t-test where each patient will serve as his or her own control to determine if the cost of frameless fractionated stereotactic radiation therapy (FFSRT) is comparable to standard treatment.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">35</enrollment>
  <condition>Metastatic Malignant Neoplasm in the Brain</condition>
  <arm_group>
    <arm_group_label>Treatment (FFSRT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo FFSRT daily over 30 minutes for 3-5 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Frameless Fractionated Stereotactic Radiation Therapy</intervention_name>
    <arm_group_label>Treatment (FFSRT)</arm_group_label>
    <other_name>FFSRT</other_name>
    <other_name>Frameless SRT</other_name>
    <other_name>FSRS</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All patients with 1-4 metastatic brain lesions who are considered eligible for&#xD;
             single-fraction, frame-based SRS, who are unable or unwilling to undergo frame-based&#xD;
             SRS&#xD;
&#xD;
          -  One to 4 untreated metastatic brain lesions&#xD;
&#xD;
          -  Each brain lesion must be less than or equal to 5 cm in diameter and not an optimal&#xD;
             surgical candidate&#xD;
&#xD;
          -  Patient must be able have a magnetic resonance imaging (MRI) of the brain for&#xD;
             treatment planning&#xD;
&#xD;
          -  Histologic confirmation of malignancy&#xD;
&#xD;
          -  For patients of childbearing potential, non-pregnant state, confirmed by negative&#xD;
             serum or urine beta-human chorionic gonadotropin (HCG) within (7) days of planned&#xD;
             radiation treatment&#xD;
&#xD;
          -  Glomerular filtration rate (GFR) adequate for intravenous (IV) contrast delivery for&#xD;
             imaging&#xD;
&#xD;
          -  No concurrent chemotherapy&#xD;
&#xD;
          -  Patient may have had prior therapy for brain metastasis, including radiosurgery and&#xD;
             surgical resection at the discretion of the treating physician however only new&#xD;
             untreated lesions will be followed on protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Five or more metastatic brain lesions&#xD;
&#xD;
          -  Brain lesion(s) greater than 5 cm in diameter&#xD;
&#xD;
          -  Lesion(s) involving the brainstem, optic chiasm or optic nerve(s)&#xD;
&#xD;
          -  Patients unable to have IV contrast for computed tomography (CT) and MRI imaging&#xD;
&#xD;
          -  Patient unable to have an MRI of the brain&#xD;
&#xD;
          -  Patients willing to be treated with frame-based gamma knife SRS at MD Anderson main&#xD;
             campus or MD Anderson at the Woodlands&#xD;
&#xD;
          -  Positive pregnant status confirmed by serum or urine pregnancy test&#xD;
&#xD;
          -  Primary small cell lung cancer, myeloma, lymphoma, leukemia, or other histologies not&#xD;
             optimally treated with SRS&#xD;
&#xD;
          -  Patients currently receiving chemotherapy/biologic/immunotherapy as these need to be&#xD;
             held during FFSRT&#xD;
&#xD;
          -  Prior whole brain radiotherapy or conventional external beam radiotherapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen Chun</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Presbyterian Hospital</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson in The Woodlands</name>
      <address>
        <city>Conroe</city>
        <state>Texas</state>
        <zip>77384</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson West Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77079</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>June 9, 2016</study_first_submitted>
  <study_first_submitted_qc>June 13, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 14, 2016</study_first_posted>
  <last_update_submitted>August 2, 2021</last_update_submitted>
  <last_update_submitted_qc>August 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

